At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the identification of actionable mutations in tumors for the development of personalized medicine for patients with lung cancer, including for the identification of patients with acquired resistance associated with T790M mutation.